FindTrial
Sign In

study on the expression and clinical significances of osteopontin and integrin av in the human nasopharyngeal carcinoma tissues

study on the expression and clinical significances of osteopontin and integrin av in the human nasopharyngeal carcinoma tissues

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OCC-12003009
Enrollment
Unknown
Registered
2012-12-25
Start date
2010-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nasopharyngeal carcinoma

Interventions

nasopharyngeal carcinoma:immunohistochemical staining and PCR
nasopharyngeal inflammation tissue:immunohistochemical staining and PCR

Sponsors

Affiliated Dongtai Hospital of Nantong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Volunteered as subjects and signed informed consent; 2. Aged 18 to 70-year-old; 3. It is UICC stage for Phase I-IV of the patients with nasopharyngeal carcinoma; 4. Histopathology or cytology to confirm the diagnosis of nasopharyngeal carcinoma; 5. Patients is first treatment process.

Exclusion criteria

Exclusion criteria: 1. Pregnancy, breast-feeding women; 2. People have other malignant tumor; 3. Patients had serious alteration in hematologic, renal, hepatic functions and Mental illness; 4. Participation in other clinical trials; 5. The researchers believe that the other condition to lead to that they dont fit into the group.

Design outcomes

Primary

MeasureTime frame
osteopontin;integrin alpha;—

Countries

China

Contacts

Public Contactyugui Zhou
yugui_z@126.com+86 18962095568

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026